We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Tracks Huntington's Disease Progression

By LabMedica International staff writers
Posted on 02 Oct 2012
Print article
Expresion of mutant huntingtin (mHTT) protein is correlated with the onset and progression of Huntington's Disease (HD) and new therapies are being developed to reduce the expression of mHTT.

Huntington’s disease is caused by an autosomal dominant pathogenic mutation, resulting in an expanded stretch of 36 or more glutamine residues in the N terminus of the huntingtin (HTT) protein and in order to evaluate these new therapies, doctors need to be able to quantify the amount of mHTT in a particular patient.

At the University College London (UK) scientists investigated the blood of eight HD gene carriers without manifestations of the disease, 10 early-stage and eight moderate-stage patients with HD, and 12 control subjects. Monocytes, T cells, and B cells were isolated using magnetic-activated cell sorting. Cheek swabs to harvest buccal epithelial cells were collected from 84 subjects from the same experimental groups. Multiple swabs and/or blood samples were taken from some subjects.

Time-resolved Förster resonance energy transfer (TR-FRET) immunoassays were used to quantify mutant and total HTT protein levels in leukocytes from patients with HD. TR-FRET analysis of an allelic series of purified HTT with increasing polyglutamine repeat lengths showed 10-fold to 20-fold higher sensitivity for mHTT than that of the wild-type protein. Total HTT levels did not differ significantly between patients with HD and controls.

Mean mHTT levels increased with successive disease stage in each leukocyte cell type, with differences between premanifest HD patients and patients with manifest HD and between premanifest and early-stage HD patients, but not between patients with early-stage and moderate-stage HD. Such an increase was not observed in buccal cells. There was a strong positive association between disease burden and mHTT in monocytes and T cells. A significant association was observed for B cells, but no evidence of an association was found in buccal epithelial cells.

Huntington's disease is a fatal, inherited neurodegenerative disorder caused by a mutation in the gene encoding huntingtin. The authors concluded that mHTT can be detected in immune cells isolated during a normal blood draw. The levels of mHTT were significantly correlated with disease symptom severity, indicating that this test could serve as a noninvasive biomarker for Huntington's disease. The study was published on September 17, 2012, in the Journal of Clinical Investigation.

Related Links:
University College London

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.